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Background and Objectives: In advanced β-cell dysfunction, proinsulin is increasingly replacing insulin as major com-
ponent of the secretion product. It has been speculated that proinsulin has at least the same adipogenic potency than 
insulin, leading to an increased tendency of lipid tissue formation in patients with late stage β-cell dysfunction.
Methods and Results: Mesenchymal stem cells obtained from liposuction material were grown in differentiation media 
containing insulin (0.01 μmol), proinsulin (0.01 μmol) or insulin+proinsulin (each 0.005 μmol). Cell culture super-
natants were taken from these experiments and an untreated control at weeks 1, 2, and 3, and were stored at −80oC 
until analysis. Cell differentiation was microscopically supervised and adiponectin concentrations were measured as 
marker for differentiation into mature lipid cells. This experiment was repeated three times. No growth of lipid cells 
and no change in adiponectin values was observed in the negative control group (after 7/14/12 days: 3.2±0.5/ 
3.3±0.1/4.4±0.5 ng/ml/12 h). A continuous differentiation into mature adipocytes (also confirmed by Red-Oil-staining) 
and a corresponding increase in adiponectin values was observed in the experiments with insulin (3.6±1.9/5.1±1.4/ 
13.3±1.5 ng/ml/12 h; p＜0.05 week 1 vs. week 3) and proinsulin (3.3±1.2/3.5±0.3/12.2±1.2 ng/ml/12 h; p＜0.05). 
Comparable effects were seen with the insulin/proinsulin combination. 
Conclusions: Proinsulin has the same adipogenic potential than insulin in vitro. Proinsulin has only 10∼20% of the 
glucose-lowering effect of insulin. It can be speculated that the adipogenic potential of proinsulin may be a large con-
tributor to the increased body weight problems in patients with type 2 diabetes and advanced β-cell dysfunction. 
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Introduction 
The pathogenetic development of type 2 diabetes is 
characterized by a hereditary β-cell dysfunction, asso-
ciated with a major hormonal activity of the visceral lipid 
tissue and a resulting chronic systemic inflammation and 
insulin resistance, which in turn increases the demand for 
insulin from the β-cells (1, 2). During a year-long devel-
opment of the disease, there is a progredient decrease in 
β-cell cleavage and processing capacity, and as con-
sequence immature precursor proteins including un- 
cleaved intact proinsulin are secreted, which can be used 
for differential diagnosis and to describe the stage of β
-cell dysfunction and insulin resistance in the individual 
patient (3, 4). In the attempt to keep and maintain a nor-
mal blood glucose control while patients gain weight and 
experience an increasing insulin resistance, the β-cells are 
forced to secrete consistently higher amounts of their secre-
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tion product. From past clinical trials with s.c. admin-
istration of intact proinsulin, it has become evident that 
proinsulin has only 10∼20% of the glucose lowering effect 
of insulin (5, 6). The requirement to produce and secrete 
more of this less effective protein may be one of the key 
contributors to a final complete β-cell exhaustion, which 
clinically leads to insulin-dependency of the patient. 
Insulin is the only hormone known to date that is capa-
ble to induce differentiation and growth of lipid tissue. 
Untreated, the absolute lack of insulin in type 1 diabetes 
results in major weight loss, cachexia and diabetic ketoaci-
dosis, while the same is usually not observed in patients 
with a relative lack of insulin during the later develop-
ment of type 2 diabetes (7). In contrary, it is well known 
that patient have a major tendency to gain further weight. 
Diet and exercise have become key pillars of an effective 
treatment of diabetes mellitus since decades (7-9). It is 
tempting to speculate that the increasing amounts of 
proinsulin, while having only a modest blood glucose-low-
ering effect, might at the same time drive differentiation 
of mesenchymal stem cells to become pre-adipocytes with 
the same lipogenic activity as completely processed 
insulin. 
Human mesenchymal stem cells (hMSCs) isolated from 
liposuction material have been described as a convenient 
model for the study of human adipogenesis, including the 
early stages of the differentiation process (10). By employ-
ing a standardized protocol for isolation and purification 
of human mesenchymal stem cells derived from lip-
osuction material with a consecutive attempt to induce 
differentiation through appropriate media, we investigated 
the potential impact of proinsulin to drive differentiation 
of stem cells into pre-adipocytes, and compared it to the 
in-vitro effect of insulin under the same laboratory 
conditions.
Materials and Methods
This work was performed in accordance with applicable 
ethical standards and German legal regulations, and the 
responsible ethical review committee approved the use of 
the liposuction material for this laboratory study.
Isolation and differentiation of adipose tissue-derived 
mesenchymal stem cells
Human adipose tissue-derived mesenchymal stem cells 
were obtained from raw human lipoaspirates from two do-
nors (a 53 yr. old female subject and a 64 yr. old male 
subject, both non-diabetic) and cultured as previously de-
scribed by Zuk et al. (11) and Zhu et al. (12). The hMSCs 
were isolated by their ability of adherence to the culture 
flask. The first medium change removed the non-adherent 
cells after three days. Briefly, raw liposuction material 
with diluted with 1x sterile phosphate-buffered saline 
(PBS) in a ratio of 1:2 at room temperature for 30 minutes 
in order to obtain a separation into a lower blood and an 
upper fat phase followed by centrifugation at 200×g for 
10 minutes at room temperature. The pellets were washed 
with 1× PBS. Remaining red blood cells were destroyed 
by incubation with erythrolysis buffer (1×10−4 M EDTA 
[pH 8.0], 0.154 M NH4Cl, 1×10−2 M KHCO3) for 10 mi-
nutes at room temperature. The upper phase was treated 
with 0.075% collagenase (type I; Sigma-Aldrich, St. Louis, 
MO) in PBS for 30 min at 37oC with gentle agitation. The 
collagenase was inactivated with an equal volume of 
DMEM/10% fetal bovine serum (FBS) and the infranatant 
centrifuged for 10 min at 200×g. The cellular pellet was 
re-suspended in DMEM/10% FBS and filtered through a 
100 μm mesh filter to remove debris. The filtrate was 
centrifuged as detailed above and plated onto conventional 
tissue culture plates in control medium (500 ml DMEM 
[4.5 g/L glucose, with L-glutamine], 50 ml fetal bovine se-
rum [heat inactivated], 5 ml penicillin/streptomycin, [10,000 
IU penicillin, 10,000 μg/ml streptomycin], 5 ml ampho-
tericin B [250 μg/ml amphotericin B], sterile filtered and 
incubated at 37oC for 30 min prior to use).
The mesenchymal stem cells were induced with differ-
entiation media (control medium with addition of dex-
amethasone [1.0 μm final], 3-isobutyl-1-methylxanthine 
[IBMX 0.5 mm final], indomethacin [0.2 mm final] and 
insulin [10.0 μm final], intact proinsulin, or the combina-
tion of both [5 μmol final each]). The same medium 
without addition of insulin or proinsulin served for the 
negative control experiments. The cells were incubated at 
37oC with twice-daily renewal of the medium and cell cul-
ture supernatants were taken from these experiments and 
an untreated control after 8 days, 17 days, and 23 days, 
respectively. They were stored at −80oC until analysis. 
Cell differentiation to the adipogenic lineage was micro-
scopically supervised and confirmed by Oil Red O stain-
ing and determination of adiponectin in the supernatant. 
All experiments were carried out in triplicate and with 
cells derived from each donor.
Oil Red O Staining
Media was removed, and cells were fixed for 60 min us-
ing a 10% formal calcium fixative (1.0 g of CaCl2, 25.0 
ml 16% paraformaldehyde (4.0% final) and 75.0 ml dis-
tilled water, all Sigma Aldrich). Thereafter, cells were 
washed two times with PBS, followed by another washing 
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Fig. 1. Differentiation of adipose-tissue derived mesenchymal stem cells into adipocytes as seen microscopically and confirmed by 
Oil-Red-Staining.
step with 70% ethanol, and 5 min incubation at room tem-
perature with Oil Red O solution (2.0 g Oil Red O powder 
in 50.0 ml 70% ethanol and 50.0 ml acetone, all SIGMA 
Aldrich). Cells were washed with 70% ethanol and tap wa-
ter and visually analyzed within 10∼15 min. A semi- 
quantitative rank scale was used for this analysis (0=no 
staining, 1=few individual cells with visible lipid gran-
ules, 2=less than 50% of visible cells with lipid granules, 
3=majority of the visible cells have lipid granules).
Measurement of total adiponectin in the supernatant
Adiponectin concentrations were measured in the super-
natant after 8 days, 17 days, and 23 days of incubation with 
daily renewal of the differentiation medium as protein se-
cretion marker for differentiation into mature lipid cells 
by means of a sensitive radioimmunoassay (Adiponectin 
RIA, Linco, St. Charles, MO). The measurements were per-
formed in triplicate with 100 μl of supernatant taken 12 
h after the last renewal of the differentiation medium.
Statistical analysis
The adiponectin results are presented as mean±STD 
and data were analysed by methods of descriptive statistics 
and interpreted in exploratory sense. Appropriate para-
metric and non-parametric methods were applied for com-
parison between day 7 and day 23. p-values＜0.05 were 
considered statistically significant.
Results
All experiments were carried out as planned and with-
out deviation from the protocol. Viable cells in an amount 
of 11.3×105 out of 13.0×105 were determined (87% via-
bly). The microscopy surveillance of the cell morphology 
revealed that no growth of lipid cells occurred in the con-
trol experiment. Also no secretion of adiponectin was ob-
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Fig. 2. The adiponectin secretion from differentiating mesenchymal 
stem cells cultivated with insulin and proinsulin in vitro confirms 
that the lipogenic effect of proinsulin is equipotent to the lipogenic 
action of insulin. ***p＜0.001.
served in the negative control experiments or could be 
seen at any of the the test days (adiponectin concen-
trations on day 8: 3.2±0.5 ng/ml, day 17: 3.3±0.1 ng/ml, 
and day 23: 4.4±0.5 ng/ml). 
The experiments conducted with addition of insulin or 
proinsulin resulted in differentiation of the cells into 
(pre-)adipocytes as proved by Oil Red O staining. Fig. 1 
shows a typical example of the microscopic appearance of 
the cells when induced by insulin at the different analysis 
days of the experiment. As can be seen, a continuous dif-
ferentiation towards mature adipocytes was observed, 
which was confirmed by a corresponding increase in adi-
ponectin values at the end of the experiment at day 23. 
With the standard insulin-containing differentiation me-
dium adiponectin levels were 3.6±1.9 ng/ml on day 8, 
5.1±1.4 ng/ml on day 17, and 13.3±1.5 ng/ml on day 23 
(p＜0.05 vs. day 8 and day 17). 
A comparable differentiation pattern was seen when in-
sulin was replaced with an equimolar amount of proinsu-
lin (day 8: 3.3±1.2 ng/ml, day 17: 3.5±0.3 ng/ml, and day 
23: 12.2±1.2 ng/ml; p＜0.05 vs. day 8 and 17) or with the 
equimolar 50:50 mixture of insulin and proinsulin (day 8: 
3.5±0.7 ng/ml, day 17: 4.0±0.2 ng/ml, and day 23: 
14.6±3.0 ng/ml; p＜0.05 vs. day 8 and 17). The compar-
ison of these results with the results derived from the con-
trol experiment are shown in Fig 2.
All differentiation experiments with media containing 
insulin and/or proinsulin resulted in similar numbers of 
differentiated cells as confirmed by cell count and Oil Red 
O staining (∼1,500 cells/cm2 with stained lipid granules), 
with a typical ranking of “3” in all cases on day 23 (see 
Fig. 1). In previous experiments, we have shown the reli-
ability of this protocol to result in adipocyte differ-
entiation also with other biomarkers not tested here 
(termination of the differentiation process usually occurs 
at around day 20) (13).
Discussion
In this study, we used human adipose tissue derived 
mesenchymal stem cells and their differentiation pattern 
as an in vitro model for obesity-associated cell differ-
entiation to identify the lipogenic potential of proinsulin 
in comparison to insulin. We assessed morphological 
changes and Oil Red O staining and measured adiponectin 
secretion into the supernatant as indication for the differ-
entiation of the stem cells towards mature adipocytes. Our 
adiponectin concentrations measured after three weeks of 
cultivation with normal insulin-containing adipogenic dif-
ferentiation medium (∼12 ng/ml/12 h) were in line with 
previously published results regarding the secretion of adi-
ponectin by mature adipocytes in vitro (14, 15). A similar 
adiponectin secretion was observed when adding proinsu-
lin or a 50/50 insulin/proinsulin mixture in equimolar 
concentrations instead of insulin to the differentiation me-
dium, while no differentiation to adipocytes occurred with-
out addition of insulin or proinsulin. 
As of today, insulin has been considered the only phys-
iological hormone in the human body that is capable to 
built-up visceral and subcutaneous lipid tissue (16). 
Alternatively, the influence of pharmaceutical drugs 
(dexamethason and rosiglitazone) may also drive stem cell 
differentiation into the adipogenic lineage in a laboratory 
setting (17). Because of the established minor but notable 
glucose-lowering effect of unprocessed proinsulin, we 
speculated that proinsulin may also have some impact on 
lipid tissue generation. By using an established in-vitro 
model of adipose tissue differentiation with mesenchymal 
stem cells derived from liposuction material, we con-
firmed a lipogenic action of proinsulin in vitro, which was 
equal to the effect observed with regular human insulin. 
Our study has several limitations, which need to be con-
sidered before interpreting the relevance of our findings 
for clinical practice. First, the experiment was a pilot ex-
periment and only performed with mesenchymal stem 
cells derived from two donors. It will be important to con-
firm our findings with stem cells derived from multiple 
donors to exclude that they are only valid for individual 
subgroups. Second, we repeated the experiment only three 
times to be able to perform at least descriptive statistics. 
However, the observed effects between weeks two and 
three of our experiments were so pronounced and homoge-
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Fig. 3. Schematic presentation of the contribution of proinsulin to 
the overall impairment of the metabolic situation in case of severe 
β-cell dysfunction.
neous that we do not believe that a larger number of meas-
urements would have change the outcome. Third and fi-
nal, translation and interpretation of in-vitro results for 
clinical practice recommendations should only be per-
formed with uppermost caution and only if other in-
dications vote for justification of such an approach.
However, even with all limitations mentioned above, 
our results might explain several well-known findings in 
patients with type 2 diabetes and prediabetes:
During the development of type 2 diabetes, increased 
concentrations of fasting and postprandial intact proinsu-
lin levels can occur as consequence of late stage β-cell dys-
function (stage III) (3, 4). Intact proinsulin has a moderate 
but notable glucose lowering effect, which may even mask 
or delay the glucose-based diagnosis of the disease (5, 6). 
Proinsulin lowers glucose only with 10% to 20% of the effi-
cacy of insulin itself, when injected subcutanelously. So 
five proinsulin molecules are required to replace the action 
of one insulin molecule (6). As a logical consequence, de-
termination of postprandial proinsulin in non-diabetic 
subjects was found to predict the development of glu-
cose-defined type 2 diabetes or macrovascular events up to 
five years in advance in a pilot study (18). In addition, this 
diagnostic value of intact proinsulin when determined in 
fasting or postprandial blood samples for prediction of dia-
betes (19-22) but also of macrovascular events (23-25) has 
been confirmed in numerous well-documented prospective 
long-term epidemiological studies in small and large pa-
tient populations during the last decades.
This β-cell dysfunction-defined “prediabetes” stage is 
not characterized by glucose abnormalities, but by normal 
glucose levels and by elevated proinsulin levels as the only 
indicative parameter. As mentioned above, the blood glu-
cose lowering potency of proinsulin is much lower than 
that of insulin and five to ten times more proinsulin needs 
to be secreted to control blood glucose in vivo. In con-
sequence, there is an increased tendency for adipocyte 
differentiation. The enhanced number of differentiated 
pre-adipocytes results in an increased hormonal activity of 
the visceral adipose tissue with secretion of proin-
flammatory hormones and cytokines (26), which consec-
utively decrease plasma adiponectin levels and increase 
chronic systemic inflammation and insulin resistance (4, 
27-29).
A main feature of this condition is insulin and leptin 
resistance as well as the production of inflammatory cyto-
kines: TNF and IL 6 and monocyte chemoattractant 
protein. It has been shown that about 30% of circulating 
IL 6 comes from adipose tissue (30). IL-6 causes insulin 
resistance by decreasing the expression of insulin re-
ceptors, decreases adipogenesis and adiponectin, and stim-
ulates hepatic gluconeogenesis (26, 30). This means that 
excess of visceral adipose tissue results in the development 
of a chronic systemic inflammatory condition, which fa-
vors the development of insulin resistance and Type 2 
diabetes.
Insulin resistance increases the pressure on the β-cells 
to produce more secretion product for glucose control (for 
a schematic representation see Fig. 3). Still patients will 
only gain weight with a positive caloric balance, i.e. if they 
eat more than what they metabolically burn. In any case, 
it can be speculated that the adipogenic potential of proin-
sulin may be a large contributor to the increased body 
weight problems, the observed chronic systemic in-
flammation (31) and associated risks in patients with type 
2 diabetes and advanced β-cell dysfunction. 
In conclusion, our pilot study has shown that proinsulin 
has a similar potential like insulin to drive mesenchymal 
stem cells into the adipogenic lineage. While this finding 
has to be confirmed in further studies, it may be in-
dicative for an important role of proinsulin in the patho-
physiology of weight gain, chronic systemic inflammation, 
and macrovascular disease in patients with type 2 diabetes 
mellitus.
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